Loading clinical trials...

Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP) | Clinical Trials | Clareo Health

Back to clinical trial search

Approved For MarketingNCT05770219

Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

The expanded access program allows people to gain access to unlicensed treatment on compassionate grounds. TAK-755 also known as rADAMTS13, is a medicine that treats people born with severe congenital...

Lead sponsor: Takeda•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

WITHDRAWNPhase 2

SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations

NCT05393999 · SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease, and more

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 24, 2025Terms

Trial snapshot

StatusAPPROVED_FOR_MARKETING

Phase—

Enrollment—

Start date—

Last updatedFeb 24, 2025

Condition

Thrombotic Thrombocytopenic Purpura (TTP)

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 24, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions